Artificial Intelligence for Drug Discovery Market Size to Surge USD 30.48 Billion by 2035; Reflecting a CAGR of 26.9%
Published : 08 Oct 2026
Author : Raghuram Nair
What is the Artificial Intelligence for Drug Discovery Market Size?
The global artificial intelligence for drug discovery market size was accounted for USD 2,800 million in 2025 and is expected to surpass USD 30,488.82 million by 2035; growing at a CAGR of 26.9% during the forecast period of 2026-2035. The global market is seen booming with expanding biotechnology capabilities, rising AI investments, and growing collaborations between technology companies, research institutions, and drug developers.
AI for Drug Discovery Market Overview
The growing acceptance of AI-driven processes among pharma and biotech players for expediting research, identifying lead candidates efficiently, and driving costs down in the traditional drug discovery path contributes to the booming artificial intelligence for drug discovery market. From target identification, virtual screening, and molecular design to lead optimization, protein engineering, and drug development; deep learning, ML, generative AI, and predictive analytics are being leveraged by market players.
Market growth is further fueled by the escalating availability of a massive storehouse of genomic, proteomic, and chemical data paired with improved cloud computing and AI infrastructure. Pharmaceutical and biotech companies' rising strategic tie-ups with tech vendors and AI start-ups present novel avenues for fostering AI innovation.
What Investment Opportunities Will Emerge in AI-Driven Drug Discovery?
- Generative AI Drug Design: Investment is expected to increase in platforms capable of designing novel molecules and optimizing drug candidates using generative models.
- AI-Powered Virtual Screening: Companies developing high-throughput AI screening technologies can attract investment as drug developers seek faster and more cost-efficient candidate identification.
- Protein and Antibody Design: AI platforms focused on protein structure prediction, protein engineering, and antibody optimization represent promising investment areas.
- AI-Biotech Startups: Venture capital and strategic investment opportunities are emerging across startups developing specialized AI platforms for target discovery, molecular modeling, and therapeutic development.
- Cloud-Based AI Platforms: Growing computational requirements are creating opportunities for scalable cloud infrastructure and AI-as-a-service solutions tailored to pharmaceutical and biotechnology research.
- Multi-Omics Analytics: Investment opportunities are expanding in AI platforms capable of integrating genomic, proteomic, transcriptomic, and other biological datasets to identify new therapeutic targets.
AI for Drug Discovery Market Segmental Outlook
| Segmentation | Dominant Segment | 2025 Share | Key Driver |
|---|---|---|---|
| By Drug Type | Small-Molecule Drugs | 55.0 | Extensive AI adoption across virtual screening, molecular property prediction, hit identification, structure-based drug design, toxicity prediction, and lead optimization. |
| By Component | Software & AI Platforms | 72.0% | Commercialization of scalable and reusable AI applications across multiple stages of the drug discovery workflow. |
| By Technology | Deep Learning | 34% | Strong ability to process complex chemical and biological datasets for molecular modeling, protein structure prediction, and drug-target interaction analysis. |
| By Deployment | Cloud | 52% | High computing and storage requirements of generative AI, deep learning, virtual screening, and large-scale biological data analysis. |
| By Organization Size | Large Pharmaceutical & Biotechnology Companies | 54% | Larger R&D budgets, proprietary datasets, established drug development pipelines, and advanced computational infrastructure. |
| By End User | Pharmaceutical Companies | 43% | Extensive R&D programs, large proprietary databases, and broad adoption of AI across drug discovery workflows. |
| By Application | Drug Design & Optimization | 39% | Increasing use of AI for de novo molecule generation, lead optimization, protein design, and candidate refinement. |
| By Therapeutic Area | Oncology | 34% | Complex disease biology, extensive genomic and proteomic datasets, and significant unmet medical needs driving AI adoption. |
What Role Will AI Play in Accelerating Drug Development?
AI is anticipated to profoundly transform drug discovery into an accelerant by reducing the time required to identify drug candidate, predicting drug properties and prioritsing molecule in laboratory as well as clinical studies. Powered AI models have the ability to analyse huge volumes of genomic, proteomic, chemical and clinical information in order to define potential drug targets and predict drugs-target interactions, optimize molecular structures, and predict toxicity and effectiveness early on.
With decreased reliance on extensive laboratory tests on individual molecule candidates and a quicker decision-making based on available data the overall productivity in R&D increases, which consequently decreases the cost and time related with the drug discovery and development.
For instance: Insilico Medicine used generative AI and ML for both the target identification and molecule design aspects of the drug discovery process, along with their AI-discovered drug candidate rentosertib (ISM001-055) in idiopathic pulmonary fibrosis (IPF) patients showing the transition in the biological drug discovery process from a biological target discovery towards the clinical development stage.
AI for Drug Discovery Market Regional Outlook
With a market share of 56% in 2025, the artificial intelligence for drug discovery market in North America dominated the market, thanks to a robust presence of a pharmaceutical and biotechnology ecosystem, numerous AI technology companies, and advanced infrastructure in research coupled with enormous datasets in the biomedical sciences.
Investments in AI based drug discovery along with the increasing need for a strong R&D and technological presence in the pharmaceutical industry and several tie-ups of technology providers, and drug developers are fueling the growth across different parts of the AI research and development space from target identification to molecule screening to drug design and clinical trials.
- United States captured a lion’s share, leading within the North American segment with growing capabilities as well as infrastructure support along with a strong fund in venturing into AI for drug discovery, thus maintaining its leadership status across the continent with a strong foothold in pharmaceutical and biotechnology along with research capabilities.
With a market share of 14.2% in 2025, the Asia Pacific regional artificial intelligence for drug discovery market is the second-largest during 2025. This increasing rise is attributed to growing research and development expenditure on pharmaceuticals. Rising biotechnology capabilities coupled with higher spending of investment into the artificial intelligence along with emerging research partnerships of technology providers, institutions and drug developers globally.
Availability of ample talent, strong focus in innovation and increasing efforts towards drug discovery are driving the second largest continent to greater potential in the market.
- China: Driven by growing pharmaceutical research and development, a strong backbone of government support in research and development, along with expanding drug development potential for domestic consumption and increase in funding across the AI and drug development platforms are some key driving factors for China to remain at the top in the Asia Pacific regional market.
Major Companies
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Novartis
- Roche
- Sanofi
- Merck & Co.
- Novo Nordisk
- NVIDIA
- Johnson & Johnson
Segments Covered
By Drug Type
- Small-Molecule Drugs
- Large-Molecule / Biologics
- Other Therapeutic Modalities
By Component
- Software/AI Platforms
- Services
By Technology
- Traditional Machine Learning
- Deep Learning
- Generative AI
- Natural Language Processing
- Other AI Technologies
By Deployment
- On-Premise
- Cloud-Based
- Hybrid
By Organization Size
- Large Pharmaceutical / Biotechnology Companies
- Small & Medium Biotechnology Companies
- Academic / Research Organizations
By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
- Other End Users
By Application
- Target Identification & Validation
- Drug Screening
- Drug Design & Optimization
- Drug Repurposing
- Preclinical Testing
- Others
By Therapeutic Area
- Oncology
- Neurology / Neurodegenerative
- Cardiovascular
- Metabolic
- Infectious
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Contact Us:
Mr. Richard Johnson
Acumen Research and Consulting
India: +91 8983225533